Remdesivir reduces Covid hospitalizations when given early, study shows

(By Matthew Herper for STAT)

Gilead’s Covid-19 drug remdesivir appeared to reduce hospitalizations by 87% in high-risk patients diagnosed early in the disease in a new study, the company said Wednesday.

The new results, which were issued in a press release, could help shore up the perception that the medicine is effective. They also could boost hopes for the use of oral antiviral drugs being developed by drug companies including Pfizer and Merck to treat people in the early stages of Covid-19.  Continue reading the article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org